Valeritas Holdings Inc. (fka VLRXQ)

[Renee]

VLRXQ: BK PLAN effective. All shares cancelled:

https://otce.finra.org/otce/dailyList?viewType=Deletions

[Renee]

VLRX changed to VLRXQ, bankruptcy. Delisted from the Nasdaq to the OTC:

https://otce.finra.org/otce/dailyList?viewType=Additions

[ClayTrader]

* * $VLRX Video Chart 02-12-2020 * *

Link to Video - click here to watch the technical chart video

[420man]

;)

[420man]

Back in .38

[aristotelisonassis]

thanks

[Atlanta1]

10:22 am ET February 10, 2020 (Dow Jones) Print
10:22 ET - Valeritas Holdings shares sink after the medical-technology company files for chapter 11 with a deal to be acquired by Denmark's Zealand Pharma for $23M, subject to a bankruptcy auction. In an SEC filing, Valeritas warns that trading in its securities during the chapter 11 process is highly speculative and poses substantial risks, and it says it doesn't expect the sale of its assets will leave any proceeds available for distribution to holders of its common stock.

[aristotelisonassis]

The agreement with Zealand, which was reached following a robust and extensive marketing process, provides total cash consideration of $23 million and includes the assumption of certain liabilities related to the ongoing business. It contemplates that Zealand, at close, would continue the Company's commercially-focused operations and retain nearly all Valeritas employees.

[Atlanta1]

wrong. they have liabilities that will take almost all of that cash.

nothing will be left for shareholders.

[aristotelisonassis]

VLRX Is receiving a 23M dollar payment with their Bankruptcy.

This play should easily go 100-200%

3M Market Cap & only 6M float

Strong buy!

[420man]

Out from.32...Tute run possible

[ClayTrader]

* * $VLRX Video Chart 02-10-2020 * *

Link to Video - click here to watch the technical chart video

[420man]

No Recovery Seen for Valeritas Common Holders -- Market Talk

10:22 am ET February 10, 2020 (Dow Jones) Print
10:22 ET - Valeritas Holdings shares sink after the medical-technology company files for chapter 11 with a deal to be acquired by Denmark's Zealand Pharma for $23M, subject to a bankruptcy auction. In an SEC filing, Valeritas warns that trading in its securities during the chapter 11 process is highly speculative and poses substantial risks, and it says it doesn't expect the sale of its assets will leave any proceeds available for distribution to holders of its common stock.

[02opida]

looking good this Thursday

[02opida]

moving up today

[ErnieBilco]

They need to cut bloat by 90% if they intend to survive. Positive step seeing the rats jump ship to find another company to trash.

Why did they have that massive amount of useless inventory? It that person still on the payroll? Get em gone.

Kinda odd that everyone is bailing AFTER bonus time.

[420man]

Lots of resignations filed, and Armistice dumped. Going down :/

[ErnieBilco]

Well, wondering if there is a bottom coming soon.

[Atlanta1]

GOOD LUCK!

[ErnieBilco]

Everyone should step out and take a risk from time to time. I did great on my Tandem bet last year when everyone was crappin on the stock.

Worst case is I have some tax losses to report.

I admit the PR was all bad with no sunshine in the forecast but like I said, it's worth the gamble knowing my personal risk tolerance and gambling habits.

[Atlanta1]

don't be foolish.

read the entire PR. they have lost their product and their customers.

worst possible scenario, leading to Chapter 11

[420man]

.58

[ErnieBilco]

OK - this is just too attractive to pass up - been nibbling today.

I hope my account is overly obese within a year or 2

[whytestocks]

News: $VLRX Valeritas Presents Positive h-Patch(TM) CBD Study Data as a Late-Breaking Presentation at the American Epilepsy Society 2019 Annual Meeting

BRIDGEWATER, N.J., Dec. 09, 2019 (GLOBE NEWSWIRE) -- Valeritas Holdings, Inc. (NASDAQ: VLRX), a medical technology company and maker of the V-Go ® Wearable Insulin Delivery device , which uses its proprietary h-Patch™ technology , announced positive data from its pr...

Got this from VLRX - Valeritas Presents Positive h-Patch(TM) CBD Study Data as a Late-Breaking Presentation at the American Epilepsy Society 2019 Annual Meeting

[02opida]

sound so good VLRX

[BottomBounce]

Who knows. The fact is they have Millions in Pure Cash. BOOOM

[BottomBounce]

$VLRX Top Institutional Holders

Armistice Capital, LLC 1,060,000 Sep 29, 2019 12.72% 1,515,800
Vanguard Group, Inc. (The) 78,739 Sep 29, 2019 0.95% 112,596
Millennium Management LLC 54,493 Sep 29, 2019 0.65% 77,924
Cutter & Co. Brokerage, Inc. 44,250 Sep 29, 2019 0.53% 63,277
Morgan Stanley 44,058 Sep 29, 2019 0.53% 63,002
Bank Of New York Mellon Corporation 38,439 Sep 29, 2019 0.46% 54,967
A.R.T. Advisors, LLC 31,559 Sep 29, 2019 0.38% 45,129
Geode Capital Management, LLC 21,512 Sep 29, 2019 0.26% 30,762
Wedbush Securities Inc 16,391 Sep 29, 2019 0.20% 23,439
Citadel Advisors LLC 14,215 Sep 29, 2019 0.17% 20,327

https://finance.yahoo.com/quote/VLRX/holders?p=VLRX&.tsrc=fin-srch

[Investing2day]

And don’t they spend around 20 million a quarter??

[BottomBounce]

**** $VLRX Has $23.17 Million in CASH!!

https://finance.yahoo.com/quote/VLRX/key-statistics?p=VLRX&.tsrc=fin-srch

[BottomBounce]

$VLRX #Diabetes The 2 analysts offering 12-month price forecasts for Valeritas Holdings Inc have a median target of 7.50, with a high estimate of 10.00 and a low estimate of 5.00. The median estimate represents a +357.32% increase from the last price of 1.64. https://money.cnn.com/quote/forecast/forecast.html?symb=vlrx

[BottomBounce]

$2 tomorrow $VLRX

[uther3055]

Good news today

[whytestocks]

News: $VLRX Valeritas' V-Go® Wearable Insulin Delivery Device Demonstrates Reductions in A1c and Daily Insulin Usage

BRIDGEWATER, N.J., Nov. 15, 2019 (GLOBE NEWSWIRE) -- Valeritas Holdings, Inc. (NASDAQ: VLRX), a medical technology company and maker of V-Go ® Wearable Insulin Delivery device , today announced additional data from the VERDICT study presented at the 19 th Annual Diabetes Technolog...

Read the whole news VLRX - Valeritas' V-Go® Wearable Insulin Delivery Device Demonstrates Reductions in A1c and Daily Insulin Usage

[BottomBounce]

$$$ $VLRX Valeritas Holdings, Inc. (NASDAQ: VLRX), a medical technology company and maker of V-Go® Wearable Insulin Delivery device, today announced additional data from the VERDICT study presented at the 19th Annual Diabetes Technology Meeting held in Bethesda, Maryland. This data demonstrated positive clinical outcomes for patients with type 2 diabetes who switched insulin therapy to V-Go from a basal-only, basal-bolus, or premix insulin regimen.

This real-world retrospective analysis was performed using electronic medical records to identify 122 patients with uncontrolled type 2 diabetes (A1c > 7.0%) who switched to V-Go from traditional insulin injection therapy regimens. The study aimed to evaluate if the baseline insulin total daily dose (TDD) on the prior regimen influenced the effectiveness of V-Go. Patients were grouped based on their prior regimen TDD into three insulin strata: < 50 U/day, 50 to 100 U/day, or > 100 U/day to evaluate clinical outcomes. After a mean duration of five months of V-Go use, significant mean reductions in A1c of 1.3%; p<0.05 were observed for each strata. In addition, the strata prescribed higher baseline doses of insulin (50 to 100 U/day and > 100 U/day) benefited from a significant reduction in TDD of 19%; p<0.0001 and 47%; p<0.0001, respectively, after switching to V-Go. The percent of patients reporting hypoglycemia decreased on V-Go.

“Optimizing insulin delivery has been shown to reduce insulin requirements and can have positive implications on patient acceptance and adherence,” said Trisha Zeidan, MD, Principal Investigator of the VERDICT Study who is affiliated with Premier Physician Network, Bull Family Diabetes Center. “In my practice, I have been able to successfully switch patients from a variety of insulin regimens and a wide range of insulin doses to V-Go. Not only has V-Go been well accepted by my patients, it has shown to improve glycemic control and, in many cases, lower insulin requirements in those previously prescribed higher doses.”

“We are excited to share these positive clinical data from the VERDICT study,” said John Timberlake, President and Chief Executive Officer of Valeritas. “We believe these results further demonstrate that, regardless of baseline insulin dose, the use of V-Go can offer patients with type 2 diabetes significant clinical benefit when switching from other insulin regimens.”

About Valeritas Holdings, Inc.

Valeritas is a commercial-stage medical technology company focused on improving health and simplifying life for people with diabetes by developing and commercializing innovative technologies. Valeritas’ flagship product, V-Go® Wearable Insulin Delivery device, is a simple, affordable, all-in-one basal-bolus insulin delivery option for adult patients requiring insulin that is worn like a patch and can eliminate the need for taking multiple daily shots. V-Go administers a continuous preset basal rate of insulin over 24 hours, and it provides discreet on-demand bolus dosing at mealtimes. It is the only basal-bolus insulin delivery device on the market today specifically designed keeping in mind the needs of type 2 diabetes patients. Headquartered in Bridgewater, New Jersey, Valeritas operates its R&D functions in Marlborough, Massachusetts.

More information is available at www.valeritas.com and our Twitter feed @Valeritas_US, www.twitter.com/Valeritas_US.

[BottomBounce]

$VLRX Big News!!! WOW

[02opida]

Recent Trades - Last 10 of 490

Time ET Ex Price Change Volume

10:02:56 Q 1.4644 0.0644 500
10:02:38 Q 1.4786 0.0786 1,600
10:02:38 Q 1.48 0.08 500
10:02:38 Q 1.48 0.08 300
10:02:38 Q 1.48 0.08 600
10:02:02 Q 1.47 0.07 50
10:01:42 Q 1.48 0.08 9
10:01:22 Q 1.49 0.09 1,000
10:01:15 Q 1.47 0.07 10
10:00:43 Q 1.47 0.07 50

[02opida]

https://www.valeritas.com/Home/default.aspx

[02opida]

10/29~7:00 ET
Valeritas Presents Positive h-Patch ™ Apomorphine Study Data at the World Congress of Neurology (WCN 2019)

[02opida]

VLTX today announced that it will release financial results for the third quarter of 2019 after the close of trading on Tuesday, November 12, 2019. Valeritas’ management team will host a corresponding conference call beginning at 4:30 p.m. ET.


Investors interested in listening to the conference call may do so by dialing [phone] for domestic callers or [phone] for international callers, using Conference ID: 7634258. A live and archived webcast of the event will be available on the “Investors” section of Valeritas’ website at: www.valeritas.com.

[uther3055]

Got my answer

[whytestocks]

News: $VLRX Valeritas Presents Positive CBD h-Patch(TM) Data at the 2nd Annual International Cannabinoid-Derived Pharmaceuticals Summit

BRIDGEWATER, N.J., Sept. 12, 2019 (GLOBE NEWSWIRE) -- Valeritas Holdings, Inc. (NASDAQ: VLRX), a medical technology company and maker of the V-Go ® Wearable Insulin Delivery device , which uses its proprietary h-Patch™ technology , announced today positive data from...

Find out more VLRX - Valeritas Presents Positive CBD h-Patch(TM) Data at the 2nd Annual International Cannabinoid-Derived Pharmaceuticals Summit

[uther3055]

Good start to the day let’s see if it holds up cbd is a big deal

[Investing2day]

But they are going to need to raise money unless we get a surprise paying partnership before year ends

[uther3055]

Looking good not only diabetes but now cbd

[whytestocks]

News: $VLRX Cannabidiol (CBD) Effectively Delivered Subcutaneously with Valeritas Proprietary h-Patch(TM) Wearable Device in Preclinical Study

- Company Plans to Explore Partnering Opportunities with CBD Therapeutics Companies -  - Company to Host a Conference Call Today, July 30, 2019 at 11:00 AM ET - BRIDGEWATER, N.J., July 30, 2019 (GLOBE NEWSWIRE) -- Valeritas Holdings, Inc. (NASDAQ: VLRX), a medical technolo...

Got this from Cannabidiol (CBD) Effectively Delivered Subcutaneously with Valeritas Proprietary h-Patch(TM) Wearable Device in Preclinical Study

[JohnConnor67]

Insulin Company VLRX Announces Strange CBD “Patch” Test Results .

Due Diligence

https://interactiveswingtrading.com/2019/07/10/vlrx-another-oppenheimer-pump-similar-to-otlk/

[BillG2436]

This looks like a pump and dump. Fluff news no changes to substantiate price increases

[#NeverPennyLand]

I’m good

[ClayTrader]

* * $VLRX Video Chart 07-10-2019 * *

Link to Video - click here to watch the technical chart video

[breynolds]

HUGE spike coming!!!
$6